Combination of advanced lung cancer inflammation index and nonalcoholic fatty liver disease fibrosis score as a promising marker for surgical procedure selection for hepatocellular carcinoma.

MLA

Hosoda, Kiyotaka, et al. “Combination of Advanced Lung Cancer Inflammation Index and Nonalcoholic Fatty Liver Disease Fibrosis Score as a Promising Marker for Surgical Procedure Selection for Hepatocellular Carcinoma.” Annals of Gastroenterological Surgery, vol. 8, no. 6, Nov. 2024, pp. 1096–106. EBSCOhost, https://doi.org/10.1002/ags3.12815.

APA

Hosoda, K., Shimizu, A., Kubota, K., Notake, T., Kitagawa, N., Yoshizawa, T., Sakai, H., Hayashi, H., Yasukawa, K., & Soejima, Y. (2024). Combination of advanced lung cancer inflammation index and nonalcoholic fatty liver disease fibrosis score as a promising marker for surgical procedure selection for hepatocellular carcinoma. Annals of Gastroenterological Surgery, 8(6), 1096–1106. https://doi.org/10.1002/ags3.12815

Chicago

Hosoda, Kiyotaka, Akira Shimizu, Koji Kubota, Tsuyoshi Notake, Noriyuki Kitagawa, Takahiro Yoshizawa, Hiroki Sakai, Hikaru Hayashi, Koya Yasukawa, and Yuji Soejima. 2024. “Combination of Advanced Lung Cancer Inflammation Index and Nonalcoholic Fatty Liver Disease Fibrosis Score as a Promising Marker for Surgical Procedure Selection for Hepatocellular Carcinoma.” Annals of Gastroenterological Surgery 8 (6): 1096–1106. doi:10.1002/ags3.12815.